Better Health for All

Exact Sciences' core products, Cologuard and Oncotype DX, are diagnostic tests for cancer, contributing to early detection and personalized treatment. The Cologuard test has detected over 623,000 cancers and precancers over 10 years, saving the U.S. healthcare system $22 billion.

The Cologuard Plus test offers 95% sensitivity for colorectal cancer detection and a 40% reduction in false positives compared to the original Cologuard. The Oncotype DX test is reliable across racial and ethnic groups for breast cancer treatment decisions. The company has no products with established negative health outcomes. Medicare and most major insurers cover the Cologuard test, with more than 96% of patients aged 45+ having no out-of-pocket costs. Medicare also covers follow-up colonoscopies after a positive Cologuard test without patient cost-sharing. The company focuses on increasing screening rates in medically underserved populations, including racial/ethnic minorities, low-income individuals, and rural communities, and has awarded $4.5 million in grants since 2022, with $1.5 million in 2024, to organizations focused on increasing colorectal cancer screening. The company explicitly states the limitations of the Cologuard test, noting that a positive result does not confirm cancer and a negative result does not rule it out, and that it is not a replacement for colonoscopy in high-risk patients. Exact Sciences is investing in a next-generation Cologuard test, which is currently under FDA review. The company also collaborates with organizations like the National Minority Quality Forum and Federally Qualified Health Centers to improve cancer screening accessibility and address disparities.

Fair Pay & Worker Respect

The CEO-to-median-employee pay ratio was 109:1 in 2024.

The company's Total Recordable Incident Rate (TRIR) was 0.49 per 200,000 hours worked in 2023, with no workplace fatalities reported for the same year. Employee engagement was high, with 95% of employees stating it's a great place to work in 2023. The voluntary employee turnover rate was 8.4% in 2023.

Fair Trade & Ethical Sourcing

No specific, quantitative data points related to fair trade and ethical sourcing, such as fair trade certification share, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, were found in the provided articles.

The articles explicitly state that these metrics are not quantified or included in the company's reports.

Honest & Fair Business

Exact Sciences has a formal whistleblower policy, including an Integrity Alertline for anonymous reporting via phone or website, and explicitly prohibits retaliation.

Employees receive training on this policy. Reports are confirmed within 7 days, and a position on the report is provided within 8 weeks (56 days). The company also maintains an International Anti-Bribery Policy, which complies with the FCPA, and includes training and reporting procedures, as well as third-party due diligence. For ethical claims, the company's Responsible Business Report mentions ISO 13485 certification, which is independently verified, and FDA inspections with no adverse findings.

Planet-Friendly Business

In 2023, Exact Sciences reported total Scope 1, 2, and 3 greenhouse gas emissions of 37,067 mt CO2e.

The company is evaluating setting a carbon reduction goal, but no SBTi-aligned targets are mentioned. Zero percent of its operational energy consumption is sourced from renewables. Total water usage in 2023 was 18,601,446 gallons, and with a 2023 revenue of $2.5 billion, this equates to 2,817 m³ per $1 million revenue. The company diverted 2,187 U.S. tons of waste from landfill through recycling, while 2,293 U.S. tons were landfilled, resulting in a waste diversion rate of 48.8%. Exact Sciences reported no adverse findings in 2023 FDA inspections and no specific regulatory actions, violations, fines, or compliance issues. The company uses TCFD disclosures to guide its reporting.

Safe & Smart Tech

Exact Sciences has a coordinated vulnerability disclosure program, acknowledging reports within 24 hours and providing an estimated remediation timeline within 10 business days.

This indicates good responsiveness to vulnerability reports. The company states a commitment to cybersecurity by design and to complying with federal, territorial, state, and local laws. However, the company explicitly restricts security testing on live systems and those in production, indicating less than 15% of critical systems undergo security testing. There is no mention of a bug bounty program, only a vulnerability disclosure program.

Zero Waste & Sustainable Products

Exact Sciences has implemented multiple waste reduction initiatives with measurable results. These include a scrap metal collection program that diverted over 30,000 pounds of metal since 2022, an IT equipment recycling program that diverted over 36,000 pounds of e-waste since 2015, and a PaperCut program that prevented over 22,000 unnecessary print jobs in 2019.

The company also replaced its waste processing system in 2019, converts Cologuard test kit boxes into fuel pellets, and has existing recycling programs for plastic whole stool containers and pipettes. The company has not reported any waste disposal violations in the past three years. While the scrap metal program collects items requiring special disposal, and an emissions study was conducted to evaluate waste disposal options, there is no specific data on the minimization of hazardous waste materials or a comprehensive hazardous waste management program beyond basic compliance.